Skip to main content

Advertisement

ADVERTISEMENT

Transplant News

News
07/17/2024
After a patient receives a solid organ transplant, long-term nutrition management is key to navigate potential adverse events from immunosuppressive therapies needed to prevent rejection, according to an invited review article published in...
After a patient receives a solid organ transplant, long-term nutrition management is key to navigate potential adverse events from immunosuppressive therapies needed to prevent rejection, according to an invited review article published in...
After a patient receives a solid...
07/17/2024
Pharmacy Learning Network
News
05/30/2024
Dr Reddy’s Laboratories Inc. is recalling 1176 bottles of sirolimus tablets for failing to meet impurities/degradation specifications.
Dr Reddy’s Laboratories Inc. is recalling 1176 bottles of sirolimus tablets for failing to meet impurities/degradation specifications.
Dr Reddy’s Laboratories Inc. is...
05/30/2024
Pharmacy Learning Network
News
09/28/2023
Jolynn Tumolo
A Class I recall has been issued for a single lot of Sandimmune Oral Solution (cyclosporine oral solution) because of product crystallization and the subsequent potential for incorrect cyclosporine dosing.
A Class I recall has been issued for a single lot of Sandimmune Oral Solution (cyclosporine oral solution) because of product crystallization and the subsequent potential for incorrect cyclosporine dosing.
A Class I recall has been issued...
09/28/2023
Pharmacy Learning Network

Advertisement

News
01/26/2022

Liz Szabo, Kaiser Health News

Liz Szabo, Kaiser Health News
Amid changing guidelines from the Centers for Disease Control and Prevention, pharmacies are denying fourth COVID-19 shots to patients with weakened immune systems.
Amid changing guidelines from the Centers for Disease Control and Prevention, pharmacies are denying fourth COVID-19 shots to patients with weakened immune systems.
Amid changing guidelines from...
01/26/2022
Pharmacy Learning Network
News
08/17/2014
Compared to standard basiliximab-based induction therapy, treatment based on alemtuzumab reduces rejection in kidney transplant recipients, according to findings from a UK-based study.
Compared to standard basiliximab-based induction therapy, treatment based on alemtuzumab reduces rejection in kidney transplant recipients, according to findings from a UK-based study.
Compared to standard...
08/17/2014
Pharmacy Learning Network